OBJECTIVE: Despite many trials of systemic chemotherapy in advanced gastric cancer, treatment after failure with first-line chemotherapy remains controversial. We prospectively assessed quality of life (QL) in gastric cancer patients treated with second-line chemotherapy. METHODS: Forty-three patients who received second-line chemotherapy for advanced gastric cancer completed the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and hospital anxiety and depression scale (HADS) at baseline and at regular intervals during and after chemotherapy. RESULTS: Compliance with QL questionnaire completion decreased to 72% after third cycle of treatment. In general, clinically meaningful improvements compared with baseline (change QLQ-C30 scores > or =10) were seen in a number of domains and items, including global health/QL, emotional function, cognitive function and all of the symptom scales and single items but appetite. There was no difference in QL between responders and non-responders (P = 0.473). At baseline, 27 (63%) patients were suspected to have anxiety or depressive disorder (HADS score > or =11), and this incidence decreased after chemotherapy (14.7 vs 9.5; P < 0.001). CONCLUSION: Improvements from baseline in QL measures and HADS scores were demonstrated in patients with advanced gastric cancer, treated with second-line chemotherapy.
OBJECTIVE: Despite many trials of systemic chemotherapy in advanced gastric cancer, treatment after failure with first-line chemotherapy remains controversial. We prospectively assessed quality of life (QL) in gastric cancerpatients treated with second-line chemotherapy. METHODS: Forty-three patients who received second-line chemotherapy for advanced gastric cancer completed the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and hospital anxiety and depression scale (HADS) at baseline and at regular intervals during and after chemotherapy. RESULTS: Compliance with QL questionnaire completion decreased to 72% after third cycle of treatment. In general, clinically meaningful improvements compared with baseline (change QLQ-C30 scores > or =10) were seen in a number of domains and items, including global health/QL, emotional function, cognitive function and all of the symptom scales and single items but appetite. There was no difference in QL between responders and non-responders (P = 0.473). At baseline, 27 (63%) patients were suspected to have anxiety or depressive disorder (HADS score > or =11), and this incidence decreased after chemotherapy (14.7 vs 9.5; P < 0.001). CONCLUSION: Improvements from baseline in QL measures and HADS scores were demonstrated in patients with advanced gastric cancer, treated with second-line chemotherapy.
Authors: Hyun Jeong Shim; Ju Young Yun; Jun Eul Hwang; Woo Kyun Bae; Sang Hee Cho; Ik Joo Chung Journal: Gastric Cancer Date: 2011-03-23 Impact factor: 7.370
Authors: Young Saing Kim; Junshik Hong; Sun Jin Sym; Se Hoon Park; Jinny Park; Eun Kyung Cho; Jae Hoon Lee; Dong Bok Shin Journal: Cancer Res Treat Date: 2010-03-31 Impact factor: 4.679
Authors: Andrew J Martin; Emma Gibbs; Katrin Sjoquist; Nick Pavlakis; John Simes; Tim Price; Jenny Shannon; Sanjeev Gill; Vikram Jain; Geoffrey Liu; George Kannourakis; Yeul Hong Kim; Jin Won Kim; David Goldstein Journal: Gastric Cancer Date: 2017-08-16 Impact factor: 7.370
Authors: Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa Journal: Arch Toxicol Date: 2021-11-02 Impact factor: 5.153
Authors: Sang Hoon Ji; Do Hyoung Lim; Seong Yoon Yi; Hyo Song Kim; Hyun Jung Jun; Kyoung Ha Kim; Myung Hee Chang; Min Jae Park; Ji Eun Uhm; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang Journal: BMC Cancer Date: 2009-04-09 Impact factor: 4.430